These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 29621036)

  • 1. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
    Bisgaier CL; Oniciu DC; Srivastava RAK
    J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo.
    Guo L; Hu WR; Lian JH; Ji W; Deng T; Qian M; Gong BQ
    Eur J Pharmacol; 2006 Dec; 551(1-3):80-6. PubMed ID: 17026988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate.
    Takacs ML; Abbott BD
    Toxicol Sci; 2007 Jan; 95(1):108-17. PubMed ID: 17047030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents.
    Fuentes E; Palomo I
    Vascul Pharmacol; 2014 Sep; 62(3):162-6. PubMed ID: 24874279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy for dyslipidaemia--current therapies and future agents.
    Bays H; Stein EA
    Expert Opin Pharmacother; 2003 Nov; 4(11):1901-38. PubMed ID: 14596646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism.
    Srivastava RAK; Cornicelli JA; Markham B; Bisgaier CL
    Mol Cell Biochem; 2018 Dec; 449(1-2):167-183. PubMed ID: 29644527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-α mediated apolipoprotein A-I, A-II and C-III.
    Liu C; Guo Q; Lu M; Li Y
    Eur J Pharmacol; 2015 Aug; 761():362-74. PubMed ID: 25979856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
    Fu J; Oveisi F; Gaetani S; Lin E; Piomelli D
    Neuropharmacology; 2005 Jun; 48(8):1147-53. PubMed ID: 15910890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phospholipase A2-modified low-density lipoprotein activates macrophage peroxisome proliferator-activated receptors.
    Namgaladze D; Morbitzer D; von Knethen A; Brüne B
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):313-20. PubMed ID: 19948841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans.
    Hertz R; Bar-Tana J
    Toxicol Lett; 1998 Dec; 102-103():85-90. PubMed ID: 10022237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid synthesis in macrophages during inflammation in vivo: effect of agonists of peroxisome proliferator activated receptors alpha and gamma and of retinoid X receptors.
    Posokhova EN; Khoshchenko OM; Chasovskikh MI; Pivovarova EN; Dushkin MI
    Biochemistry (Mosc); 2008 Mar; 73(3):296-304. PubMed ID: 18393765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors increase human sebum production.
    Trivedi NR; Cong Z; Nelson AM; Albert AJ; Rosamilia LL; Sivarajah S; Gilliland KL; Liu W; Mauger DT; Gabbay RA; Thiboutot DM
    J Invest Dermatol; 2006 Sep; 126(9):2002-9. PubMed ID: 16675962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Persea americana (avocado) fruit extract on the level of expression of adiponectin and PPAR-γ in rats subjected to experimental hyperlipidemia and obesity.
    Padmanabhan M; Arumugam G
    J Complement Integr Med; 2014 Jun; 11(2):107-19. PubMed ID: 24770838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation.
    Krogsdam AM; Nielsen CA; Neve S; Holst D; Helledie T; Thomsen B; Bendixen C; Mandrup S; Kristiansen K
    Biochem J; 2002 Apr; 363(Pt 1):157-65. PubMed ID: 11903058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate.
    Peters JM; Zhou YC; Ram PA; Lee SS; Gonzalez FJ; Waxman DJ
    Mol Pharmacol; 1996 Jul; 50(1):67-74. PubMed ID: 8700121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.